Ownership and insider activity for iBio, Inc. (IBIO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis.
Price
| Price | $1.18 |
| Market Cap | $19M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.1M | $15.9M | $4.4M | $55.1M | $77.4M | $22.7M | $7.3M | $14.2M | $8.6M | $56.4M |
| Short-term Investments | 0 | 0 | 0 | 0 | $19.6M | $10.8M | 0 | 0 | 0 | $31.6M |
| Receivables | $175000 | $75000 | $97000 | $5.6M | $5.5M | $6.1M | $204000 | $713000 | $105000 | $1.1M |
| Inventory | $26000 | 0 | 0 | $798000 | $27000 | $3.9M | 0 | 0 | 0 | 0 |
| Total Current Assets | $8.6M | $16.3M | $4.8M | $61.7M | $104.6M | $45.1M | $26.3M | $15.7M | $9.7M | $92.2M |
| Property, Plant & Equipment | $25.6M | $25.2M | $24.4M | $31.3M | $34.7M | $41.8M | $7.6M | $6.4M | $5.3M | $4.8M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $1.8M | $1.6M | $1.4M | $1.1M | $952000 | $4.9M | $5.4M | $5.4M | $6.8M | $1.8M |
| Total Assets | $36.0M | $43.1M | $30.6M | $94.2M | $147.0M | $99.4M | $41.2M | $28.7M | $23.2M | $99.1M |
| Accounts Payable | $332000 | $790000 | $1.0M | $1.8M | $2.3M | $4.3M | $1.8M | $358000 | $2.2M | $4.4M |
| Short-term Debt | 0 | 0 | 0 | $261000 | $600000 | $22.2M | $13.6M | $218000 | $766000 | 0 |
| Total Current Liabilities | $2.0M | $2.0M | $3.5M | $5.2M | $6.6M | $30.4M | $21.6M | $3.8M | $6.1M | $11.7M |
| Long-term Debt | 0 | 0 | 0 | $339000 | 0 | 0 | 0 | $766000 | 0 | 0 |
| Total Liabilities | $27.1M | $26.9M | $28.1M | $37.6M | $38.4M | $35.9M | $25.8M | $7.4M | $8.3M | $13.4M |
| Retained Earnings | -$72.1M | -$88.2M | -$105.8M | -$150.4M | -$173.6M | -$223.9M | -$288.9M | -$313.8M | -$332.2M | -$365.3M |
| Total Equity | $8.9M | $16.2M | $2.5M | $56.6M | $108.6M | $63.5M | $15.4M | $21.3M | $14.9M | $85.7M |
| Total Debt | $25.3M | $25.1M | $24.9M | $32.9M | $32.7M | $25.8M | $17.1M | $4.5M | $3.5M | $2.2M |
| Net Debt | $17.2M | $9.1M | $20.5M | -$22.2M | -$64.3M | -$7.8M | $9.7M | -$9.8M | -$5.1M | -$85.8M |
| Working Capital | $6.6M | $14.2M | $1.4M | $56.5M | $98.0M | $14.6M | $4.7M | $11.8M | $3.6M | $80.5M |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 7.85 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -21.93 |
Profitability
| Return on Equity | -38.55% |
| Return on Invested Capital | -39.97% |
| Return on Assets | -33.34% |
| Gross Margin | 100.00% |
| Operating Margin | -35141.00% |
| Net Margin | -33044.00% |
Related companies: ANTX · BOLD · CVKD · INTS · ITRM · KLTO · PLUR
Explore sector: Healthcare · Biotechnology
More sections of IBIO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks